Opsona Therapeutics Ltd. Initiates a Phase II Study With OPN-305, a First-in Class Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
5/7/2013 11:19:59 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DUBLIN--(BUSINESS WIRE)--Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases, today announced that it has initiated a phase II clinical trial in renal transplant patients at high risk of delayed graft function with its lead drug candidate OPN-305.
Help employers find you! Check out all the jobs and post your resume.
comments powered by